Predictive factors and outcomes of immune-related adverse events in Chinese patients treated with immune checkpoint inhibitors: a real-world retrospective study
BackgroundThe widespread clinical application of immune checkpoint inhibitors (ICIs) has brought immune-related adverse events (irAEs) to the forefront of oncology management. However, systematic investigations focusing on the efficacy and irAE profile…